Clinical Trial Detail

NCT ID NCT03473756
Title Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma (FORT-2)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Bayer
Indications

urethra transitional cell carcinoma

bladder urothelial carcinoma

renal pelvis transitional cell carcinoma

ureter transitional cell carcinoma

Therapies

Atezolizumab

Atezolizumab + Rogaratinib

Age Groups: senior adult

Additional content available in CKB BOOST